Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) PT at $21.07

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $21.07.

IOVA has been the topic of several research analyst reports. Piper Sandler lowered their price objective on Iovance Biotherapeutics from $10.00 to $7.50 and set a "neutral" rating on the stock in a report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors have recently made changes to their positions in IOVA. B. Riley Wealth Advisors Inc. lifted its holdings in Iovance Biotherapeutics by 39.4% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company's stock worth $144,000 after buying an additional 5,500 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $47,000. Neo Ivy Capital Management bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $3,353,000. Stempoint Capital LP bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $7,026,000. Finally, Shay Capital LLC bought a new position in Iovance Biotherapeutics in the 4th quarter worth about $188,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Iovance Biotherapeutics Stock Down 1.7 %

Iovance Biotherapeutics stock traded down $0.09 during midday trading on Friday, reaching $5.26. 12,517,597 shares of the stock traded hands, compared to its average volume of 8,530,706. Iovance Biotherapeutics has a 12 month low of $5.05 and a 12 month high of $18.33. The stock's fifty day moving average is $6.31 and its 200-day moving average is $8.64. The stock has a market cap of $1.60 billion, a P/E ratio of -3.53 and a beta of 0.54.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. On average, equities analysts predict that Iovance Biotherapeutics will post -1.24 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.